Telix Pharmaceuticals Ltd — Capital/Financing Update 2018

Nov 26, 2018

==> picture [143 x 79] intentionally omitted <==

Atlab Acquisition - Voluntary Escrow Shares to be released

Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”) advises that 2,083,925 fully paid ordinary shares (Shares) voluntarily escrowed from 11 September 2018 by new shareholders under the Atlab acquisition will be released from escrow on 11 December 2018. These Shares are already quoted on the ASX. Full details of the voluntary escrow arrangements are as follows:

Number of fully paid ordinary shares Escrow release date subject to voluntary escrow

2,083,925 11-Dec-18 6,251,752 11-Sep-19 6,501,854 11-Sep-20

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (Japan) and Indianapolis (USA). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

Company Secretary Melanie Farris melanie.farris@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorization in any jurisdiction, including the United States and Europe.